Aqueous Vascular Endothelial Growth Factor as a Predictor of Macular Thickening Following Cataract Surgery in Patients With Diabetes Mellitus

American Journal of Ophthalmology

Volumn 148, Issue 6, 2009, Pages

  Hartnett, M Elizabeth ^a   Tinkham, Nicholas ^a   Paynter, Lauren ^b   Geisen, Pete ^a   Rosenberg, Pinchas ^a   Koch, Gary ^b   Cohen, Kenneth L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; VASCULOTROPIN;

AGED; ARTICLE; BLOOD SAMPLING; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LASER SURGERY; MACULA DENSA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHACOEMULSIFICATION; PILOT STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA EDEMA; SLIT LAMP; TREATMENT OUTCOME;

EID: 70449628897     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.07.014     Document Type: Article

References (36)

1. Jaffe G.J., Burton T.C., Kuhn E., Prescott A., and Hartz A. Progression of nonproliferative diabetic retinopathy and visual outcome after extracapsular cataract extraction and intraocular lens implantation. Am J Ophthalmol 114 (1992) 448-456
2. Henderson B.A., Kim J.Y., Ament C.S., Ferrufino-Ponce Z.K., Grabowska A., and Cremers S.L. Clinical pseudophakic cystoid macular edema: Risk factors for development and duration after treatment. J Cataract Refract Surg 33 (2007) 1550-1558
3. Chew E.Y., Benson W.E., Remaley N.A., et al. Results after lens extraction in patients with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 25. Arch Ophthalmol 117 (1999) 1600-1606
4. Suto C., Hori S., Kato S., Muraoka K., and Kitano S. Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol 124 (2006) 38-45
5. Benson W.E., Brown G.C., Tasman W., McNamara J.A., and Vander J.F. Extracapsular cataract extraction with placement of a posterior chamber lens in patients with diabetic retinopathy. Ophthalmology 100 (1993) 730-738
6. Escaravage Jr. G.K., Cohen K.L., Patel S.B., Hartnett M.E., Armstrong B.D., and Janowski C.M. Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. J Cataract Refract Surg 32 (2006) 803-811
7. Kim S.J., Equi R., and Bressler N.M. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 114 (2007) 881-889
8. Cardillo J.A., Melo L.A., Costa R.A., et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 112 (2005) 1557-1563
9. Larsson J., Zhu M., Sutter F., and Gillies M.C. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 139 (2005) 802-806
10. Aiello L.P., Bursell S., Clermont A., et al. Vascular endothelial growth factor induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46 (1997) 1473-1480
11. Campochiaro P.A. Targeted pharmacotherapy of retinal diseases with ranibizumab. Drugs Today (Barc) 43 (2007) 529-537
12. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114 (2007) 1860-1867
13. Arevalo J.F., Garcia-Amaris R.A., Roca J.A., et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: Pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 33 (2007) 2098-2105
14. Spitzer M.S., Ziemssen F., Yoeruek E., Petermeier K., Aisenbrey S., and Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 34 (2008) 70-75
15. Funatsu H., Yamashita H., Noma H., Shimizu E., Mimura T., and Hori S. Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg 28 (2002) 1355-1363
16. Roh M.I., Kim H.S., Song J.H., Lim J.B., and Kwon O.W. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 116 (2009) 80-86
17. Wedrychowicz A., Dziatkowiak H., Nazim J., and Sztefko K. Insulin-like growth factor-1 and its binding proteins, IGFBP-1 and IGFBP-3, in adolescents with type-1 diabetes mellitus and microalbuminuria. Horm Res 63 (2005) 245-251
18. Uthra S., Raman R., Mukesh B.N., et al. Diabetic retinopathy and IGF-1 gene polymorphic cytosine-adenine repeats in a Southern Indian cohort. Ophthalmic Res 39 (2007) 294-299
19. Chantelau E., and Frystyk J. Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration-a case report. Growth Horm IGF Res 15 (2005) 130-135
20. Ruberte J., Ayuso E., Navarro M., et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 113 (2004) 1149-1157
21. Smith L.E.H., Kopchick J.J., Chen W., et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276 (1997) 1706-1709
22. Smith L.E.H., Shen W., Peruzzu C., et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5 (1999) 1390-1395
23. Wilkinson C.P., Ferris III F.L., Klein R.E., et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110 (2003) 1677-1682
24. Early Treatment Diabetic Retinopathy Study. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report No. 1. Arch Ophthalmol 103 (1985) 1796-1806
25. Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 114 (2007) 1520-1525
26. Lobo C.L., Faria P.M., Soares M.A., Bernardes R.C., and Cunha-Vaz J.G. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg 30 (2004) 752-760
27. Funatsu H., Yamashita H., Noma H., Mimura T., Yamashita T., and Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133 (2002) 70-77
28. Funatsu H., Yamashita H., Nakamura S., et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113 (2006) 294-301
29. Funatsu H., Yamashita H., Ikeda T., Mimura T., Eguchi S., and Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110 (2003) 1690-1696
30. Poon R.T., Ho J.W., Tong C.S., Lau C., Ng I.O., and Fan S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91 (2004) 1354-1360
31. George M.L., Eccles S.A., Tutton M.G., Abulafi A.M., and Swift R.I. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?. Clin Cancer Res 6 (2000) 3147-3152
32. Kim S.J., Choi I.K., Park K.H., et al. Serum Vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol 34 (2004) 184-190
33. Lee J.K., Hong Y.J., Han C.J., Hwang D.Y., and Hong S.I. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int J Oncol 17 (2000) 149-152
34. Wynendaele W., Derua R., Hoylaerts M.F., et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?. Ann Oncol 10 (1999) 965-971
35. Cavusoglu A.C., Bilgili S., Alaluf A., et al. Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy. Ann Ophthalmol (Skokie) 39 (2007) 205-208
36. Sydorova M., and Lee M.S. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res 37 (2005) 188-190